ANA-ENA, LIA 17 IgG at Lahore PCR Lab

ANA-ENA, LIA 17 IgG at Lahore PCR Lab

The Antinuclear Antibody and Extractable Nuclear Antigen, Line Immunoassay 17 IgG (ANA-ENA, LIA 17 IgG) is a highly specialized, state-of-the-art immunological diagnostic panel designed to detect and differentiate 17 distinct autoantibodies in human serum. At Lahore PCR Lab, located in Lahore, Pakistan, this advanced test serves as a cornerstone for diagnosing complex systemic autoimmune rheumatic diseases (SARD). Autoimmune disorders occur when the body’s immune system mistakenly identifies its own cellular components as foreign invaders, producing autoantibodies that target intracellular proteins and nucleic acids. Traditional screening methods, such as indirect immunofluorescence (IFA), indicate the presence of antinuclear antibodies but cannot pinpoint the specific target antigens. The LIA 17 IgG panel addresses this clinical limitation by simultaneously profiling 17 specific IgG autoantibodies, providing clinicians with an unparalleled level of diagnostic precision.

The technology behind the Line Immunoassay is highly sophisticated. Purified recombinant or native antigens are applied as discrete parallel lines on a nitrocellulose membrane strip. When a patient’s blood sample is introduced, any specific IgG autoantibodies present in the serum bind to their corresponding antigen lines. Following a series of washing steps to remove unbound proteins, an enzyme-conjugated anti-human IgG antibody is added, which binds to the antigen-antibody complexes. A chromogenic substrate is then introduced, producing distinct, visible dark bands on the strip. The intensity of these bands is directly proportional to the concentration of the specific autoantibodies, which is then analyzed semi-quantitatively using automated scanning systems at Lahore PCR Lab. This method offers exceptional sensitivity and specificity, making it an invaluable tool for differentiating overlapping autoimmune syndromes, predicting organ involvement, and monitoring disease progression.

The anatomical scope of this test is systemic, as the autoantibodies evaluated target fundamental cellular machinery present in almost every tissue of the human body, including the cell nucleus, cytoplasm, and mitotic apparatus. Consequently, the clinical utility of the ANA-ENA, LIA 17 IgG panel spans multiple medical specialties, primarily rheumatology, clinical immunology, nephrology, neurology, and dermatology. By identifying the exact molecular targets of the autoimmune response, this panel helps physicians distinguish between conditions such as Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome, Systemic Sclerosis (Scleroderma), Mixed Connective Tissue Disease (MCTD), and Idiopathic Inflammatory Myopathies. Early and precise diagnosis through Lahore PCR Lab enables the timely initiation of targeted immunosuppressive or immunomodulatory therapies, significantly improving long-term patient outcomes and preventing irreversible tissue damage.

Clinical Procedure: What to Expect

Patient Preparation

To ensure the highest level of diagnostic accuracy and prevent potential interference with the immunological assay, patients undergoing the ANA-ENA, LIA 17 IgG test at Lahore PCR Lab should adhere to the following preparation guidelines:

• No Strict Fasting Required: Fasting is generally not mandatory for this blood test. Patients may consume food and water normally unless instructed otherwise by their referring physician.
• Medication Disclosure: It is crucial to inform the laboratory staff and your physician of all medications you are currently taking. Immunosuppressive drugs, corticosteroids, and certain biologic therapies can suppress antibody levels, potentially leading to false-negative results.
• Hydration: Drinking adequate amounts of water before the procedure is highly recommended, as it facilitates easier venipuncture and ensures a smooth sample collection process.
• Avoid Biotin Supplements: High doses of biotin (Vitamin B7) can interfere with certain immunoassays. It is advisable to avoid biotin-containing supplements for at least 48 hours prior to blood collection.
• Timing of the Test: While the test can be performed at any time of day, consistency in timing is beneficial if the test is being repeated to monitor antibody titers over time.

During the Procedure

The sample collection process at Lahore PCR Lab is conducted under strict aseptic conditions by experienced phlebotomists to ensure patient safety and sample integrity:

• Patient Positioning: The patient is comfortably seated, and the preferred arm is positioned on a supportive armrest.
• Vein Selection and Sanitization: The phlebotomist applies a tourniquet above the elbow to locate a suitable vein, typically the median cubital vein. The site is then thoroughly sanitized with an antiseptic alcohol swab.
• Venipuncture: A sterile, single-use needle is inserted into the vein to collect a small volume of blood (approximately 3 to 5 mL) into a gold-top serum separator tube (SST) or a red-top plain tube.
• Post-Collection Care: The needle is gently withdrawn, and immediate pressure is applied to the puncture site with a sterile cotton ball to stop any bleeding. A small adhesive bandage is then applied.
• Sample Processing: The collected blood is allowed to clot naturally at room temperature before being centrifuged at high speeds to separate the serum. The isolated serum, containing the IgG autoantibodies, is then processed using the advanced Line Immunoassay platform.
• Safety and Comfort: The entire venipuncture procedure takes less than five minutes and involves minimal discomfort, comparable to a mild pinch.

When is a ANA-ENA, LIA 17 IgG Performed?

Systemic Lupus Erythematosus (SLE) Diagnosis

Physicians frequently request the ANA-ENA, LIA 17 IgG panel when a patient exhibits clinical signs suggestive of Systemic Lupus Erythematosus. SLE is a chronic, multi-system autoimmune disease characterized by widespread inflammation. Common symptoms prompting this investigation include a malar (butterfly) rash across the cheeks and nose, photosensitivity, unexplained prolonged fever, joint pain with swelling, and extreme fatigue. The presence of specific autoantibodies like anti-dsDNA and anti-Sm within the 17-antigen panel helps confirm an SLE diagnosis, allowing rheumatologists to initiate appropriate therapeutic protocols to manage systemic inflammation and protect vital organs.

Sjögren’s Syndrome Evaluation

Sjögren’s Syndrome is a systemic autoimmune disorder primarily targeting the exocrine glands, leading to classic symptoms of severe dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). Patients may also experience joint pain, skin dryness, and profound fatigue. When these symptoms present, clinicians order the LIA 17 IgG panel to screen for anti-SSA (Ro60 and Ro52) and anti-SSB (La) antibodies. Detecting these specific markers is essential for establishing a definitive diagnosis of Sjögren’s Syndrome, distinguishing it from other causes of sicca symptoms, and assessing the risk of extraglandular manifestations.

Systemic Sclerosis (Scleroderma) Investigation

Systemic Sclerosis is a rare connective tissue disease characterized by progressive skin thickening, vascular abnormalities, and fibrotic changes in internal organs such as the lungs, heart, and gastrointestinal tract. Early symptoms often include Raynaud’s phenomenon (color changes in fingers and toes in response to cold), swollen fingers, and skin tightening. The ANA-ENA, LIA 17 IgG panel is critical in these cases, as it detects anti-Scl-70 and anti-CENP-B antibodies. These markers help differentiate between diffuse and limited cutaneous systemic sclerosis, guiding the clinical management and monitoring of pulmonary and cardiac complications.

Mixed Connective Tissue Disease (MCTD) Detection

Mixed Connective Tissue Disease is an overlap syndrome that combines clinical features of SLE, systemic sclerosis, and polymyositis. Patients often present with a complex array of symptoms, including swollen hands, Raynaud’s phenomenon, joint inflammation, muscle weakness, and esophageal dysfunction. Because the clinical picture is highly variable, physicians rely on the LIA 17 IgG panel to identify high titers of anti-U1-RNP antibodies. The isolated presence of anti-U1-RNP in the absence of other lupus-specific antibodies is the diagnostic hallmark of MCTD, allowing for precise classification and targeted therapy.

Polymyositis and Dermatomyositis Screening

Idiopathic inflammatory myopathies, including polymyositis and dermatomyositis, are characterized by chronic muscle inflammation leading to progressive, symmetrical proximal muscle weakness. Patients with dermatomyositis also present with distinct skin rashes, such as Gottron’s papules on the knuckles and a heliotrope rash on the eyelids. When muscle weakness, elevated muscle enzymes, or characteristic rashes are observed, the LIA 17 IgG panel is ordered to detect myositis-specific antibodies like anti-Jo-1, anti-Mi-2, and anti-PM-Scl. These markers confirm the diagnosis, help predict interstitial lung disease risk, and guide immunosuppressive treatment strategies.

What Does a ANA-ENA, LIA 17 IgG Detect?

The ANA-ENA, LIA 17 IgG panel at Lahore PCR Lab is designed to detect a comprehensive spectrum of 17 distinct autoantibodies, each associated with specific clinical entities and pathological processes:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE); strongly associated with lupus nephritis and disease activity.
• Anti-Nucleosome: An early marker for SLE, often present in patients with active lupus nephritis.
• Anti-Histone: Strongly associated with drug-induced lupus erythematosus, as well as idiopathic SLE.
• Anti-Ribosomal P-protein: Highly specific for SLE, particularly associated with neuropsychiatric lupus and lupus hepatitis.
• Anti-Sm (Smith): Pathognomonic for SLE; included in the classification criteria for the disease.
• Anti-Sm/RNP: Found in patients with SLE and Mixed Connective Tissue Disease (MCTD).
• Anti-SSA/Ro 60 kDa: Associated with Sjögren’s syndrome, SLE, and neonatal lupus.
• Anti-Ro 52 kDa: Frequently found in Sjögren’s syndrome, systemic sclerosis, myositis, and associated with congenital heart block.
• Anti-SSB/La: Closely linked with Sjögren’s syndrome and SLE; usually co-exists with anti-SSA.
• Anti-Scl-70 (Topoisomerase I): Highly specific marker for diffuse cutaneous systemic sclerosis; indicates a higher risk of pulmonary fibrosis.
• Anti-CENP-B (Centromere Protein B): Marker for limited cutaneous systemic sclerosis (CREST syndrome) and primary biliary cholangitis.
• Anti-Jo-1 (Histidyl-tRNA Synthetase): The most common myositis-specific antibody; strongly associated with antisynthetase syndrome and interstitial lung disease.
• Anti-PM-Scl (PM-Scl 100/75): Associated with polymyositis-systemic sclerosis overlap syndrome.
• Anti-Mi-2: Highly specific for classic dermatomyositis, generally associated with a favorable response to therapy.
• Anti-PCNA (Proliferating Cell Nuclear Antigen): Rare but highly specific marker for SLE, often associated with nephritis and vasculitis.
• Anti-M2 (Antimitochondrial M2): Highly specific marker for Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
• Anti-DFS70: Often present in healthy individuals; when found in isolation, it helps rule out systemic autoimmune rheumatic diseases.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic results are critical for patient care and clinical decision-making. The ANA-ENA, LIA 17 IgG panel is processed using automated, high-throughput line immunoassay systems to ensure both speed and accuracy. The standard turnaround time for this comprehensive panel is typically 24 to 48 hours from the time of sample collection. Once the analysis is complete, the results undergo a rigorous multi-stage verification process by our qualified clinical pathologists to ensure absolute accuracy.

Patients and referring physicians can access reports easily through Lahore PCR Lab’s secure online portal. An automated SMS notification containing a direct download link and login credentials is sent to the patient’s registered mobile number as soon as the report is finalized. Additionally, physical copies of the reports can be collected directly from our main diagnostic center in Lahore. This seamless digital reporting system ensures that patients can share their findings with their consulting specialists without delay, facilitating prompt medical intervention.

ANA-ENA, LIA 17 IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA Antibody	Negative (No band detected)	Positive (Strongly indicative of SLE and active lupus nephritis)
Anti-Sm Antibody	Negative (No band detected)	Positive (Highly specific diagnostic marker for SLE)
Anti-U1-RNP Antibody	Negative (No band detected)	Positive (Diagnostic marker for Mixed Connective Tissue Disease)
Anti-SSA/Ro (60/52) Antibody	Negative (No band detected)	Positive (Suggestive of Sjögren’s, SLE, or risk of neonatal lupus)
Anti-SSB/La Antibody	Negative (No band detected)	Positive (Associated with Sjögren’s syndrome and SLE)
Anti-Scl-70 Antibody	Negative (No band detected)	Positive (Indicates diffuse cutaneous systemic sclerosis)
Anti-CENP-B Antibody	Negative (No band detected)	Positive (Indicates limited systemic sclerosis / CREST syndrome)
Anti-Jo-1 Antibody	Negative (No band detected)	Positive (Suggestive of myositis and antisynthetase syndrome)
Anti-M2 Antibody	Negative (No band detected)	Positive (Strongly associated with Primary Biliary Cholangitis)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for ANA-ENA, LIA 17 IgG?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified pathologists, immunologists, and technologists specializing in autoimmune diagnostics.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication throughout the testing process.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality control protocols to ensure reliable results.
• Professional Reporting: Comprehensive, easy-to-read reports with clear semi-quantitative values for all 17 autoantibodies.
• Modern Diagnostic Approach: Utilizing state-of-the-art automated Line Immunoassay technology for superior sensitivity and specificity.
• Comfortable Environment: Our diagnostic center in Lahore provides a clean, welcoming, and professional environment for all patients.
• Convenient Location: Easily accessible main facility and collection centers located across Lahore.
• Commitment to Accurate Diagnosis: Dedicated to providing precise immunological profiling to assist clinicians in early and accurate disease management.